Alza Corporation

Corium Corporation

Corium International, Inc.

Other

Eun Soo Lee

Su Il Yum

Parminder Singh

Amit K Jain

Robert M Gale

Tyler Watanabe

Felix T Theeuwes

Terry L Burkoth

Lina T Taskovich

Patrick S Wong

Alejandro C Zaffaroni

Diane E Nedberge

Ivan W Chin

Victor Goetz

Appala Sagi

David E Edgren

David J Enscore

Michel J Cormier

Richard D Hamlin

Pieter Bonsen

Nieves M Crisologo

Russell D Beste

Scott A Bura

Su Ii Yum

Patrick Wong S L

Einar Sudmann

Su Ll Yum

Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

Systems comprising a composite backing and methods for long term transdermal administration

Systems and methods for long term transdermal administration

An adhesive matrix and adhesive formulation are described. The adhesive matrix is comprised of a hydrophilic domain and a hydrophobic domain, and a therapeutically active agent contained in the matrix in a supersaturated, stable, condition. The hydrophilic domain and the hydrophobic domain are co-soluble in a solvent system, to provide a homogeneous blend in which the active agent is solubilized. The proportion of the hydrophilic domain and hydrophobic domain is selected to optimize, or maximize, solubility of active agent in the matrix.

Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent

Methods, compositions, and devices for transdermally administering an active agent such as memantine are provided.

Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point

A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

Methods for treating alzheimer's disease with donepezil transdermal system

Transdermal delivery systems for the systemic delivery of memantine are described, wherein the system comprises a drug reservoir layer and an adhesive layer, optionally together with one or more intermediate and/or supporting layers, wherein the drug reservoir layer comprises an acrylate polymer or copolymer, a permeation enhancer, a carrier, and memantine base generated in situ by reaction of a memantine salt and an alkaline salt. Compositions and kits comprising the various components, e.g., drug reservoir and/or adhesive compositions are described. Methods relating to treatment of CNS disorders, e.g., Alzheimer's disease and/or dementia, using the aforementioned transdermal delivery devices and/or compositions are also described.

Memantine transdermal delivery systems

Donepezil transdermal delivery system

In an aspect of the invention, a composition for making a patch for the transdermal delivery of tamsulosin is provided. The composition comprises (a) at least about 1 wt % tamsulosin or a pharmaceutically acceptable salt of tamsulosin, (b) at least about 40 wt % polyisobutylene adhesive or hydrophobic synthetic rubber adhesive, (c) about 1-20 wt % of an aprotic solvent in which tamsulosin dissolves readily, (d) about 1-20 wt % of an unsaturated fatty acid or an alpha-hydroxy acid or a mixture of unsaturated fatty acids or alpha-hydroxy acids or of both unsaturated fatty acids and alpha-hydroxy acids, (e) a lipophilic permeation enhancer, and (f) a matrix modifier.

Transdermal administration of tamsulosin

A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25.

Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery

Growing community of inventors

Redwood City, CA, United States of America

Eun Soo Lee